ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / INCY
MEDP (80) CRL (63) ICLR (71) IQV (64) ⌘ Pro Terminal →

Incyte Corp. (INCY) — RQD Stock Rating Cockpit

$120.39 +3.07% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $121.34

Incyte Corp. (INCY) earns a Roarable Rating of A- (Buy) with 84/100 RQD Confidence. High-quality cash engine (93% profit margin, 42% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 84/100 (A-) historically ranked in the Top 6% of excess returns over the next 90 days (+8.9% avg 90D alpha vs SPY • 72.6% hit rate) →
ROARABLE A- • STRONG BUY Cap $23.68B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INCY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INCY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Incyte Corp. (NASDAQ: INCY) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 84/100 at a spot price of $120.39 (+3.07% 1D, market cap $23.68B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 17/20, and SEC Balance-Sheet Forensics 18/20. Across 1016 tracked Health Care issuers, INCY ranks #6 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INCY compare to MEDP and CRL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), INCY carries a Roarable A- (84/100 RQD), trailing P/E of 18.4x, gross margin of 92.8%, and ROIC of 42.4%. By comparison, MEDP (Medpace Holdings Inc.) holds a B+ grade (80/100 RQD, P/E 42.0x, ROIC 27.9%, cap $18.95B) and CRL (Charles River Laboratories International Inc.) posts a C grade (63/100 RQD, P/E N/A, ROIC 0.4%, cap $17.95B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INCY?
▼

Per INCY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000879169), Incyte Corp. generated $5.14B in revenue (+21.2% YoY), $1.29B in net income, and $1.18B in free cash flow against $6.96B in total assets and $805.7M in total debt. Key quantitative strengths: Strong cash generator (93% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $121.34 (+0.79%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 23% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 84/100 (A-) historically ranked in the Top 6% of excess returns over the next 90 days (+8.9% avg 90D alpha vs SPY • 72.6% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSTRONG BUY • A-
025507510084
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A- · Rk A
Cash (19)Whales (12)SEC (18)Macro (17)CEO (18)
Each axis scored 0–20
12M PRICE TARGET CONE+11.7% Base Target
$159 Bull$134 Base$99 Bear
📬 FREE INCY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INCY)Realized 20D OHLCV Swing Band: ±6.1%
Deterministic 5-Pillar Attribution (84/100 Composite)
🔍 WHY INCY SCORES 84/100 (A-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 23% FCF Margin ($1.18B FCF) & 92.8% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (21% of score)

Altman Z-Score 10.04 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning12/20 pts (-8 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-8 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
76
Grade B+$108.62+7.4% Next Q
Q2 (-2Q)
79
Grade A-$116.62+0% Next Q
Q3 (-1Q)
81
Grade A-$116.60+3.3% Next Q
Current
84
Grade A-$120.39+8.9% Hist 90D α
Trajectory: B+ (76) → A- (84)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the INCY Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 84/100 (A-) score, INCY faces multiple-compression risk if 18.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) — any gross margin slip below 90.3% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($120.04) or 200D SMA ($108.17) invalidates the momentum regime and cuts Target Base ($134.48) toward Bear Floor ($98.72).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INCY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “INCY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 84%NO 16%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
5030 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
10.04>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
9 / 99-Pt Accounting
52-WEEK LASER RANGE72% OF RANGE
L: $89$120.39H: $133
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (93% profit margin and healthy balance-sheet cushion).

Factor Grade: A+RQD 19 / 20
2. Big Money & Insiders● BUYING
Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: BRQD 30 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: ARQD 35 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bullish on INCY

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (95)

42.4% ROIC with 92.8% gross margin and 4.99% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (90)

Altman-Z 10.04 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (78)

30/40 institutional & smart-money positioning score with 17/20 macro alignment.

Bull Case: Why Buyers Like INCY
  • ✓Strong cash generator (93% profit margin)—profits are backed by real money, not accounting tricks.
  • ✓Company leadership has skin in the game with net positive insider conviction.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (INCY Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
INCY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +23.93%▼ DESCENDING CHANNEL
2026-11-02O $116.9H $120.4L $116.8C $120.4VOL 3.05M
RES: $125.4SUP: $105.2SMA50: $120.0SMA200: $108.2
$135.4$123.7$112.0$100.3$88.54RES $125.4SUP $105.2$120.42026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INCY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INCY Butterfly Map → + Track INCY →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
11.7%/yr Implied 5Y Growth

vs. +21.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INCY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INCY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INCY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INCY)

Health Care Rank #6 of 1016 ⚔️ MEDP vs INCY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INCY vs. MEDP, CRL, ICLR, IQV)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Incyte Corp. (INCY) ranks #6 by composite RQD confidence (84/100, grade A-) and #66 by equity capitalization ($23.68B). Within this direct 5-issuer industry benchmark cohort, INCY leads on earnings valuation at 18.4x trailing P/E, while INCY leads on capital efficiency and profitability with 42.4% ROIC and 92.8% gross margin. INCY currently leads its immediate peer cohort in composite quantitative strength at 84/100 (A-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
INCY ACTIVE
Incyte Corp.
A- 84/100 18.4x 92.8% 42.4% +3.07% $23.68B Benchmark Subject
MEDP
Medpace Holdings Inc.
B+ 80/100 42.0x — 27.9% -3.77% $18.95B /medp-vs-incy →
CRL
Charles River Laboratories International Inc.
C 63/100 — — 0.4% -4.44% $17.95B /crl-vs-incy →
ICLR
ICON plc
B- 71/100 71.9x — 3.1% -1.91% $16.50B /iclr-vs-incy →
IQV
IQVIA Holdings Inc.
C 64/100 33.3x — 9.4% -2.81% $45.33B /iqv-vs-incy →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000879169

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Incyte Corp. (INCY) reported GAAP revenue of $5.14B (+21.2% vs. FY2024 revenue of $4.24B , and +39.1% cumulative change since FY2023) , GAAP net income of $1.29B, operating cash flow of $1.41B, and free cash flow of $1.18B (+718.2% YoY). On the balance sheet, INCY closed FY2025 with $6.96B in total assets against $805.7M in total debt (Altman Z-Score: 10.04, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $5.14B $1.29B $1.41B $1.18B $6.96B $805.7M
FY2024 (FY) 2024-12-31 $4.24B $32.6M $335.3M $144.5M $5.44B $898.5M
FY2023 (FY) 2023-12-31 $3.70B $597.6M $496.5M $330.2M $13.02B $3.05B

3. INCY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INCY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Incyte Corp. (NASDAQ: INCY) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 84/100 at a spot price of $120.39 (+3.07% 1D, market cap $23.68B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 17/20, and SEC Balance-Sheet Forensics 18/20. Across 1016 tracked Health Care issuers, INCY ranks #6 in composite RQD confidence.

How does INCY compare to MEDP and CRL in the Health Care sector?

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), INCY carries a Roarable A- (84/100 RQD), trailing P/E of 18.4x, gross margin of 92.8%, and ROIC of 42.4%. By comparison, MEDP (Medpace Holdings Inc.) holds a B+ grade (80/100 RQD, P/E 42.0x, ROIC 27.9%, cap $18.95B) and CRL (Charles River Laboratories International Inc.) posts a C grade (63/100 RQD, P/E N/A, ROIC 0.4%, cap $17.95B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INCY?

Per INCY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000879169), Incyte Corp. generated $5.14B in revenue (+21.2% YoY), $1.29B in net income, and $1.18B in free cash flow against $6.96B in total assets and $805.7M in total debt. Key quantitative strengths: Strong cash generator (93% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INCY trading relative to its 50-day, 200-day, and 52-week technical levels?

INCY last traded at $120.39 (+3.07% on volume of 2,840,752 shares), positioning the stock +0.29% above its 50-day simple moving average ($120.04) and +11.30% above its 200-day simple moving average ($108.17). Across its 52-week range of $89.25 to $132.60, INCY sits at the 71.8% percentile with a 14-day RSI of 50.0 (NEUTRAL RANGE) and an implied next-earnings move of ±6.1% ($113.05 to $127.73).

INCY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell INCY stock right now?

Incyte Corp. (INCY) currently earns a Roarable Rating of A- (Buy — BUY) with 84/100 RQD Confidence. High-quality cash engine (93% profit margin, 42% return on capital) with steady institutional support.

What is INCY's 12-month price target and RQD AI Jury consensus?

INCY's 12-month base price target is $134.48 (range $98.72 to $158.69), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: INCY RQD Cockpit INCY 12M Forecast INCY Earnings & Move INCY Dividends & DRIP INCY Insiders & 13F INCY Whale Options INCY Profit Sankey INCY News & Why
ROARABLE RATING BRIEF • RQD 84/100 (A-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

INCY — Incyte Corp.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:13:07Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, INCY scores 84 out of 100 with a letter grade of A-, labeled "Roarable Buy — Superior Risk/Reward." The strongest pillar is the Fundamental Cash Engine at 19 of 20, supported by ROIC of 42.4% and an FCF yield of 4.99%, which suggests the business generates substantial returns on invested capital relative to the cash it produces. The Forensic Balance Sheet pillar scores 18 of 20 (Altman Z 10.04; Piotroski F 9/9; Debt/Equity 0.15), indicating a low-leverage balance sheet with strong financial-health indicators. Insider Conviction scores 18 of 20, reflecting SEC Form 4 and Congressional PTR cluster flow as recorded in the rating. Macro Regime Fit scores 17 of 20, consistent with a Beta of 1.01. The weakest pillar is Whale 13F Flow at 12 of 20, which points to more modest institutional accumulation and options positioning signals than the other four pillars. For a prospective investor, the upside drivers implied by the rating are the cash-generation and balance-sheet strength; the main valuation tradeoff is that the stock trades at a P/E (TTM) of 18.4 and EV/EBITDA of 12.5 against the rating's strong fundamentals, so the rating does not imply the price is inexpensive in absolute terms. This is an analytical summary of the rating's inputs, not personalized financial advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
116.8$23.68B18.415.512.56.350%1.01$89.25 - $132.642.4%

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$5141.2M$1514.9M$1286.7MN/A$1182.1M$3097.8M$805.7M
FY 2024$4241.2M$61.4M$32.6MN/A$144.5M$1687.8M$898.5M
FY 2023$3695.6M$620.5M$597.6MN/A$330.2MN/A$3047.0M

Per the SEC financials, revenue rose from $3695.6M (FY 2023) to $5141.2M (FY 2025), and net income moved from $32.6M in FY 2024 to $1286.7M in FY 2025. Per the Roarable RQD rating, ROIC is 42.4%, and the forensic pillar cites an Altman Z of 10.04, a Piotroski F of 9/9, and Debt/Equity of 0.15. Reported debt fell from $3047.0M (FY 2023) to $805.7M (FY 2025). Per the market data, the net margin is 25%.

Open Questions

  • What are the specific product lines and revenue mix behind the FY 2025 revenue of $5141.2M?
  • The FY 2025 EPS and FY 2024 and FY 2023 EPS are reported as N/A; what are the reported per-share figures for each period?
  • Cash for FY 2023 is N/A; what was the reported cash balance that year?
  • What drove the swing in net income from $32.6M (FY 2024) to $1286.7M (FY 2025), and how much of it is recurring?
  • Which pipeline assets underlie the Stifel price-target raise, and what are their stated timelines?

INCY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Incyte Corp. (INCY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to INCY Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INCY Bull vs. Bear Conversation Board — What's Your Call at $120.39?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INCY 🐻 33% BEARISH CONVICTION
1. Pick Your Side on INCY:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $137.82 (+18.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is INCY (A- • RQD 84/100) a Buy at $116.80?

Welcome to the INCY (Incyte Corp.) Roar Pit. Current RQD Composite is 84/100 (Roarable Buy — Superior Risk/Reward) in Biotechnology: Commercial Physical & Biological Resarch. Bulls point to capital efficiency (42.4% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $95.78 (-18.0%)
Spot @ $116.80

Pump the brakes on INCY — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on INCY, but look at what you are paying: 18.4x trailing P/E with 92.8% gross margins. Unless Incyte Corp. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $135.49 (+16.0%)
Spot @ $116.80

INCY cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on INCY, the market is fixating on short-term headline noise in Biotechnology: Commercial Physical & Biological Resarch and ignoring the balance sheet and cash flow trajectory. At $116.80 (52-wk range $89.25 - $132.60), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%